The stark reality we're facing is that if the cost of Ozempic and Wegovy doesn't drop, countless Americans with diabetes and obesity might be priced out of crucial treatments.
Doctors are sounding the alarm, particularly for lower-income and minority communities, who are disproportionately affected.
The consequences aren't just financial; they're life-threatening.
How do we address this critical healthcare issue that impacts so many lives?
The Senate HELP Committee investigates why Novo Nordisk charges Americans with diabetes and obesity exorbitantly high prices for Ozempic and Wegovy.
